NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $78.83 -1.53 (-1.90%) (As of 07/1/2024 ET) Add Compare Share Share Today's Range$78.68▼$81.8850-Day Range$78.83▼$102.8752-Week Range$78.68▼$125.83Volume887,003 shsAverage Volume718,521 shsMarket Capitalization$18.74 billionP/E Ratio157.66Dividend YieldN/APrice Target$111.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside41.7% Upside$111.70 Price TargetShort InterestHealthy1.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.00) to ($2.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector572nd out of 916 stocksBiological Products, Except Diagnostic Industry91st out of 153 stocks 3.1 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageBioNTech has only been the subject of 4 research reports in the past 90 days.Read more about BioNTech's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.16% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently decreased by 9.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 2.0 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BioNTech this week, compared to 8 articles on an average week.Search InterestOnly 18 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease in the coming year, from ($2.00) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 157.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 138.14.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 157.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 172.65.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon’s Next IPO Could be Bigger than TeslaYou now have a second chance with what I believe could be Elon’s next big IPO.Click here now and I’ll show you a way to profit BEFORE it goes public… About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesJune 27, 2024 | globenewswire.comPfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European UnionJune 26, 2024 | americanbankingnews.comBioNTech's (BNTX) Buy Rating Reiterated at HC WainwrightJuly 1, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” June 24, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Shares Gap Up to $84.64June 24, 2024 | globenewswire.comBioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate CancerJune 17, 2024 | benzinga.comWhy Is Pfizer Partner BioNTech Stock Trading Lower On Monday?June 17, 2024 | reuters.comUS FDA puts partial clinical hold on BioNTech's early-stage study of cancer drugJune 13, 2024 | seekingalpha.comBioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm SkepticalJuly 1, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” June 1, 2024 | globenewswire.comInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)May 29, 2024 | msn.comBioNTech Secures $145M for African Vaccine Production NetworkMay 29, 2024 | uk.finance.yahoo.comBioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine EcosystemMay 29, 2024 | markets.businessinsider.comBioNTech And CEPI Expand Strategic Partnership To Boost African Vaccine EcosystemMay 29, 2024 | globenewswire.comBioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine EcosystemMay 28, 2024 | marketwatch.comStock Market Today: Dow falls over 250 points, Nvidia leads Nasdaq to fresh recordMay 28, 2024 | msn.comBioNTech gains antibody drug conjugate platform license from Chinese biotechMay 28, 2024 | markets.businessinsider.comReiterating Buy on BioNTech Amid Strategic Growth and Upcoming CatalystsMay 27, 2024 | msn.comModerna Was Among The Best Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio?May 26, 2024 | prnewswire.comMediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnershipMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioNTech SE on Strong Pipeline and Strategic ExpansionMay 24, 2024 | markets.businessinsider.comCritical Insights From BioNTech Analyst Ratings: What You Need To KnowMay 24, 2024 | fool.comWhy Vaccine Stocks Rallied This WeekMay 24, 2024 | markets.businessinsider.comBuy Rating on BioNTech SE Amidst Undervaluation and Strong Pipeline ProspectsMay 21, 2024 | globenewswire.comBioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024May 21, 2024 | globenewswire.comMedigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced TermMay 17, 2024 | theglobeandmail.comModerna wins COVID shot patent case against Pfizer-BioNTech in EuropeMay 17, 2024 | reuters.comModerna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reportsSee More Headlines Company Calendar Last Earnings5/06/2024Today7/01/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$111.70 High Stock Price Target$171.00 Low Stock Price Target$90.00 Potential Upside/Downside+41.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio157.66 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins4.01% Pretax Margin5.55% Return on Equity0.55% Return on Assets0.49% Debt Debt-to-Equity Ratio0.01 Current Ratio11.38 Quick Ratio11.16 Sales & Book Value Annual Sales$4.13 billion Price / Sales4.53 Cash Flow$4.97 per share Price / Cash Flow15.85 Book Value$92.17 per share Price / Book0.86Miscellaneous Outstanding Shares237,730,000Free Float192,083,000Market Cap$18.74 billion OptionableOptionable Beta0.23 Social Links Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.25MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $823.67kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.44MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $846.46kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.04MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $817.16kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $612.05kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsModernaNASDAQ:MRNABiogenNASDAQ:BIIBargenxNASDAQ:ARGXNeurocrine BiosciencesNASDAQ:NBIXBio-TechneNASDAQ:TECHView All CompetitorsInstitutional OwnershipEverSource Wealth Advisors LLCBought 252 shares on 6/11/2024Ownership: 0.000%DekaBank Deutsche GirozentraleSold 13,174 shares on 6/4/2024Ownership: 0.173%Walleye Trading LLCSold 22,600 shares on 5/17/2024Ownership: 0.000%Tidal Investments LLCBought 7,625 shares on 5/17/2024Ownership: 0.003%Dynasty Wealth Management LLCBought 4,242 shares on 5/16/2024Ownership: 0.002%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech SE is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. The company is currently developing FixVac product candidates, such as BNT111 and BNT112, which are in various stages of clinical trials. Recent developments show promising results in the company's pipeline, indicating potential future growth. BioNTech SE has a strong focus on innovation and research, positioning itself as a leader in the biotechnology industry. The current stock price of BioNTech SE reflects positive investor sentiment and growth potential. Cons Investors should be bearish about investing in BioNTech SE for these reasons: Biotechnology investments can be volatile and subject to regulatory approvals, which may impact the company's financial performance. Competition in the biotechnology sector is intense, with other companies also developing immunotherapies for similar indications. Market uncertainties and global economic conditions can affect the demand for BioNTech SE's products and services. Investing in biotechnology companies carries inherent risks related to clinical trial outcomes and product commercialization. Fluctuations in the stock price of BioNTech SE may be influenced by external factors beyond the company's control. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 1, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com. BNTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price target for 2024? 10 Wall Street research analysts have issued 1 year price objectives for BioNTech's shares. Their BNTX share price targets range from $90.00 to $171.00. On average, they predict the company's share price to reach $111.70 in the next year. This suggests a possible upside of 41.7% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2024? BioNTech's stock was trading at $105.54 on January 1st, 2024. Since then, BNTX shares have decreased by 25.3% and is now trading at $78.83. View the best growth stocks for 2024 here. Are investors shorting BioNTech? BioNTech saw a drop in short interest in June. As of June 15th, there was short interest totaling 2,740,000 shares, a drop of 9.9% from the May 31st total of 3,040,000 shares. Based on an average trading volume of 718,500 shares, the days-to-cover ratio is presently 3.8 days. Approximately 1.2% of the shares of the company are short sold. View BioNTech's Short Interest. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our BNTX earnings forecast. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) announced its earnings results on Monday, May, 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.60. The firm earned $203.69 million during the quarter, compared to the consensus estimate of $589.96 million. BioNTech had a trailing twelve-month return on equity of 0.55% and a net margin of 4.01%. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), iShares Biotechnology ETF (IBB) and Range Cancer Therapeutics ETF (CNCR). What guidance has BioNTech issued on next quarter's earnings? BioNTech issued an update on its FY 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.7 billion-$3.4 billion, compared to the consensus revenue estimate of $3.0 billion. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More This page (NASDAQ:BNTX) was last updated on 7/1/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But t...Banyan Hill Publishing | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredCatalyst Could Trigger 10,000% Crypto GainsFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding BioNTech SE You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.